Patient characteristics stratified by chemotherapy regimens before and after PSM for patients with all stages, early-stage, and advanced-stage disease
| Characteristic . | Total . | Before PSM . | After PSM . | ||||
|---|---|---|---|---|---|---|---|
| Non–ANT based . | ANT based . | P . | Non–ANT based . | ANT based . | P . | ||
| All stages (n = 2560) | 2560 | 1351 | 1209 | 1114 | 1114 | ||
| Male sex | 1811 (70.7) | 956 (70.8) | 855 (70.7) | .981 | 731 (65.6) | 766 (68.8) | .114 |
| Age >60 y | 309 (12.1) | 165(12.2) | 144 (11.9) | .815 | 129 (11.6) | 128 (11.5) | .947 |
| B symptoms | 1106 (43.2) | 575 (42.6) | 531 (43.9) | .488 | 560 (50.3) | 525 (47.1) | .138 |
| ECOG score ≥2 | 198 (7.7) | 89 (6.6) | 109 (9.0) | .022 | 72 (6.5) | 72 (6.5) | 1.000 |
| Stage I-II | 2226 (87.0) | 1156 (85.6) | 1070 (88.5) | .028 | 979 (87.9) | 979 (87.9) | 1.000 |
| PTI | 1466 (57.3) | 777 (57.5) | 689 (57.0) | .789 | 635 (57.0) | 638 (57.3) | .898 |
| Elevated LDH | 807 (31.5) | 392 (29.0) | 415 (34.3) | .004 | 346 (31.1) | 346 (31.1) | 1.000 |
| UADT site | 2400 (93.8) | 1248 (92.4) | 1152 (95.3) | .002 | 1060 (95.2) | 1060 (95.2) | 1.000 |
| Regional LN involvement | 984 (38.4) | 564 (41.7) | 420 (34.7) | <.001 | 410 (36.8) | 410 (36.8) | 1.000 |
| Distant LN involvement | 160 (6.2) | 88 (6.5) | 72 (6.0) | .560 | 61 (5.5) | 70 (6.3) | .418 |
| Stage I-II (n = 2226) | 2226 | 1156 | 1070 | 968 | 968 | ||
| Male sex | 1576 (70.8) | 812 (70.2) | 764 (71.4) | .548 | 625 (64.6) | 664 (68.6) | .060 |
| Age >60 y | 271 (12.2) | 145 (12.5) | 126 (11.8) | .580 | 116 (12.0) | 112 (11.6) | .778 |
| B symptoms | 929 (41.7) | 469 (40.6) | 460 (43.0) | .247 | 405 (41.8) | 405 (41.8) | 1.000 |
| ECOG score ≥2 | 126 (5.7) | 46 (4.0) | 80 (7.5) | <.001 | 37 (3.8) | 37 (3.8) | 1.000 |
| Stage II | 788 (35.4) | 447 (38.7) | 341 (31.9) | .001 | 330 (34.1) | 330 (34.1) | 1.000 |
| Elevated LDH | 634 (28.5) | 293 (25.3) | 341 (31.9) | .001 | 272 (28.1) | 272 (28.1) | 1.000 |
| PTI | 1269 (57.0) | 647 (56.0) | 622 (58.1) | .303 | 552 (57.0) | 552 (57.0) | 1.000 |
| UADT site | 2152 (96.7) | 1119 (96.8) | 1033 (96.5) | .216 | 933 (96.4) | 943 (97.4) | .190 |
| Stage III-IV (n = 334) | 334 | 195 | 139 | 101 | 101 | ||
| Male sex | 235 (70.4) | 144 (73.8) | 91 (65.5) | .098 | 65 (64.4) | 60 (59.4) | .469 |
| Age >60 y | 38 (11.4) | 20 (10.3) | 18 (12.9) | .445 | 10 (9.9) | 10 (9.9) | 1.000 |
| B symptoms | 177 (53.0) | 106 (54.4) | 71 (51.1) | .554 | 52 (51.5) | 52 (51.5) | 1.000 |
| ECOG score ≥2 | 72 (21.6) | 43 (22.1) | 29 (20.9) | .795 | 34 (33.7) | 26 (25.7) | .218 |
| Elevated LDH | 173 (51.8) | 99 (50.8) | 74 (53.2) | .565 | 49 (48.5) | 49 (48.5) | 1.000 |
| PTI | 197 (59.0) | 130 (66.7) | 67 (48.2) | .001 | 64 (63.4) | 64 (63.4) | 1.000 |
| UADT site | 236 (70.7) | 129 (66.2) | 107 (77.0) | .032 | 77 (76.2) | 77 (76.2) | 1.000 |
| Distant LN involvement | 160 (47.9) | 130 (66.7) | 67 (48.2) | .001 | 45 (44.6) | 45 (44.6) | 1.000 |
| Characteristic . | Total . | Before PSM . | After PSM . | ||||
|---|---|---|---|---|---|---|---|
| Non–ANT based . | ANT based . | P . | Non–ANT based . | ANT based . | P . | ||
| All stages (n = 2560) | 2560 | 1351 | 1209 | 1114 | 1114 | ||
| Male sex | 1811 (70.7) | 956 (70.8) | 855 (70.7) | .981 | 731 (65.6) | 766 (68.8) | .114 |
| Age >60 y | 309 (12.1) | 165(12.2) | 144 (11.9) | .815 | 129 (11.6) | 128 (11.5) | .947 |
| B symptoms | 1106 (43.2) | 575 (42.6) | 531 (43.9) | .488 | 560 (50.3) | 525 (47.1) | .138 |
| ECOG score ≥2 | 198 (7.7) | 89 (6.6) | 109 (9.0) | .022 | 72 (6.5) | 72 (6.5) | 1.000 |
| Stage I-II | 2226 (87.0) | 1156 (85.6) | 1070 (88.5) | .028 | 979 (87.9) | 979 (87.9) | 1.000 |
| PTI | 1466 (57.3) | 777 (57.5) | 689 (57.0) | .789 | 635 (57.0) | 638 (57.3) | .898 |
| Elevated LDH | 807 (31.5) | 392 (29.0) | 415 (34.3) | .004 | 346 (31.1) | 346 (31.1) | 1.000 |
| UADT site | 2400 (93.8) | 1248 (92.4) | 1152 (95.3) | .002 | 1060 (95.2) | 1060 (95.2) | 1.000 |
| Regional LN involvement | 984 (38.4) | 564 (41.7) | 420 (34.7) | <.001 | 410 (36.8) | 410 (36.8) | 1.000 |
| Distant LN involvement | 160 (6.2) | 88 (6.5) | 72 (6.0) | .560 | 61 (5.5) | 70 (6.3) | .418 |
| Stage I-II (n = 2226) | 2226 | 1156 | 1070 | 968 | 968 | ||
| Male sex | 1576 (70.8) | 812 (70.2) | 764 (71.4) | .548 | 625 (64.6) | 664 (68.6) | .060 |
| Age >60 y | 271 (12.2) | 145 (12.5) | 126 (11.8) | .580 | 116 (12.0) | 112 (11.6) | .778 |
| B symptoms | 929 (41.7) | 469 (40.6) | 460 (43.0) | .247 | 405 (41.8) | 405 (41.8) | 1.000 |
| ECOG score ≥2 | 126 (5.7) | 46 (4.0) | 80 (7.5) | <.001 | 37 (3.8) | 37 (3.8) | 1.000 |
| Stage II | 788 (35.4) | 447 (38.7) | 341 (31.9) | .001 | 330 (34.1) | 330 (34.1) | 1.000 |
| Elevated LDH | 634 (28.5) | 293 (25.3) | 341 (31.9) | .001 | 272 (28.1) | 272 (28.1) | 1.000 |
| PTI | 1269 (57.0) | 647 (56.0) | 622 (58.1) | .303 | 552 (57.0) | 552 (57.0) | 1.000 |
| UADT site | 2152 (96.7) | 1119 (96.8) | 1033 (96.5) | .216 | 933 (96.4) | 943 (97.4) | .190 |
| Stage III-IV (n = 334) | 334 | 195 | 139 | 101 | 101 | ||
| Male sex | 235 (70.4) | 144 (73.8) | 91 (65.5) | .098 | 65 (64.4) | 60 (59.4) | .469 |
| Age >60 y | 38 (11.4) | 20 (10.3) | 18 (12.9) | .445 | 10 (9.9) | 10 (9.9) | 1.000 |
| B symptoms | 177 (53.0) | 106 (54.4) | 71 (51.1) | .554 | 52 (51.5) | 52 (51.5) | 1.000 |
| ECOG score ≥2 | 72 (21.6) | 43 (22.1) | 29 (20.9) | .795 | 34 (33.7) | 26 (25.7) | .218 |
| Elevated LDH | 173 (51.8) | 99 (50.8) | 74 (53.2) | .565 | 49 (48.5) | 49 (48.5) | 1.000 |
| PTI | 197 (59.0) | 130 (66.7) | 67 (48.2) | .001 | 64 (63.4) | 64 (63.4) | 1.000 |
| UADT site | 236 (70.7) | 129 (66.2) | 107 (77.0) | .032 | 77 (76.2) | 77 (76.2) | 1.000 |
| Distant LN involvement | 160 (47.9) | 130 (66.7) | 67 (48.2) | .001 | 45 (44.6) | 45 (44.6) | 1.000 |
Data are presented as n (%) of patients.
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; LN, lymph node.